| OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript |
OncoCyte Corporation (NASDAQ:OCX ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Executive Officer Andrea James - Chief Financial Officer Ekke Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG Mason Carrico - Stephens Thomas Flaten - Lake Street Mike Matson - Needham Yuan Zhi - B. Riley Securities Gabby Woody Welcome everyone and thank you for joining us to discuss OncoCyte's First Quarter 2025 Results. |
seekingalpha.com |
2025-05-13 03:32:22 |
Czytaj oryginał (ang.) |
| Oncocyte Reports Q1 2025 Results and Business Progress |
IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results: |
globenewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| Oncocyte to Release First Quarter 2025 Results on May 12, 2025 |
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. |
globenewswire.com |
2025-05-07 20:10:00 |
Czytaj oryginał (ang.) |
| Oncocyte to Release First Quarter 2025 Results on May 12, 2025 |
IRVINE, Calif., May 7, 2025 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. |
prismmediawire.com |
2025-05-07 20:08:19 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for May 6th |
MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025. |
zacks.com |
2025-05-06 15:00:43 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for May 6th |
MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025. |
zacks.com |
2025-05-06 12:45:34 |
Czytaj oryginał (ang.) |
| Oncocyte Provides Positive Update on Clinical Trial Progress |
IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. |
globenewswire.com |
2025-04-30 12:30:00 |
Czytaj oryginał (ang.) |
| Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity |
Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay. |
globenewswire.com |
2025-04-29 12:30:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 24th |
YARIY, OCX, SMHI, VTMX and BANF have been added to the Zacks Rank #1 (Strong Buy) List on April 24, 2025. |
zacks.com |
2025-04-24 11:35:38 |
Czytaj oryginał (ang.) |
| OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? |
OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-04-07 17:00:42 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference |
IRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. |
prismmediawire.com |
2025-04-02 12:47:36 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference |
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. |
globenewswire.com |
2025-04-02 12:45:00 |
Czytaj oryginał (ang.) |
| OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript |
OncoCyte Corporation (NASDAQ:OCX ) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - CSO Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham Mason Carrico - Stephens Gabby Woody Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. |
seekingalpha.com |
2025-03-24 20:53:50 |
Czytaj oryginał (ang.) |
| Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts |
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. |
prismmediawire.com |
2025-03-24 18:05:34 |
Czytaj oryginał (ang.) |
| Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts |
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. |
globenewswire.com |
2025-03-24 18:05:00 |
Czytaj oryginał (ang.) |
| Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 |
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. |
globenewswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 |
IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. |
prismmediawire.com |
2025-03-18 18:01:08 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. |
globenewswire.com |
2025-02-11 10:30:00 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. |
prismmediawire.com |
2025-02-11 10:29:26 |
Czytaj oryginał (ang.) |
| Oncocyte Prices $29.1 Million Equity Offering |
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”). |
prismmediawire.com |
2025-02-10 10:30:04 |
Czytaj oryginał (ang.) |
| Oncocyte Prices $29.1 Million Equity Offering |
Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”). |
globenewswire.com |
2025-02-10 10:30:00 |
Czytaj oryginał (ang.) |
| Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer |
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. |
globenewswire.com |
2025-01-08 10:30:00 |
Czytaj oryginał (ang.) |
| Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer |
Irvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. |
prismmediawire.com |
2025-01-08 10:26:11 |
Czytaj oryginał (ang.) |
| Oncocyte Expands Market Opportunity for VitaGraft™ Kidney |
Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of patients will lose their allograft within 3 years compared to the 96% five-year allograft survival for patients without DSA.1 Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. IRVINE, Calif. |
globenewswire.com |
2025-01-06 18:05:00 |
Czytaj oryginał (ang.) |
| Oncocyte Expands Market Opportunity for VitaGraft™ Kidney |
Irvine, Calif., January 6, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology, today announced a significant milestone in the advancement of patient care for kidney transplant patients. |
prismmediawire.com |
2025-01-06 18:00:32 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings |
January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. |
prismmediawire.com |
2024-12-09 18:05:26 |
Czytaj oryginał (ang.) |
| Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings |
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. |
globenewswire.com |
2024-12-09 18:05:00 |
Czytaj oryginał (ang.) |
| Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study |
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. |
prismmediawire.com |
2024-12-06 09:55:37 |
Czytaj oryginał (ang.) |
| Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study |
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. |
globenewswire.com |
2024-12-04 18:15:00 |
Czytaj oryginał (ang.) |
| Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms |
IRVINE, Calif., Dec. 02, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal Nephrology Dialysis Transplantation. |
prismmediawire.com |
2024-12-02 21:14:27 |
Czytaj oryginał (ang.) |
| Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms |
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal, Nephrology Dialysis Transplantation. |
globenewswire.com |
2024-12-02 18:05:00 |
Czytaj oryginał (ang.) |
| OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript |
OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator today. |
seekingalpha.com |
2024-11-12 22:52:05 |
Czytaj oryginał (ang.) |
| Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 |
IRVINE, Calif., Nov. |
prismmediawire.com |
2024-11-12 18:06:47 |
Czytaj oryginał (ang.) |
| Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 |
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. |
globenewswire.com |
2024-11-06 18:45:00 |
Czytaj oryginał (ang.) |
| Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 |
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. |
prismmediawire.com |
2024-11-06 18:42:35 |
Czytaj oryginał (ang.) |
| Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles |
IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. |
prismmediawire.com |
2024-10-16 20:16:30 |
Czytaj oryginał (ang.) |
| Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles |
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. |
globenewswire.com |
2024-10-16 20:15:00 |
Czytaj oryginał (ang.) |
| Insider Buying Slows, but Not for 7 These Buyers |
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season. |
247wallst.com |
2024-10-13 13:45:27 |
Czytaj oryginał (ang.) |
| Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial |
IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™. |
prismmediawire.com |
2024-10-08 12:31:36 |
Czytaj oryginał (ang.) |
| Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial |
Results published in peer-reviewed journal , Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. |
globenewswire.com |
2024-10-08 12:30:00 |
Czytaj oryginał (ang.) |
| Oncocyte Signs Leading Transplant Centers in US and Germany |
IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. |
prismmediawire.com |
2024-10-02 23:13:03 |
Czytaj oryginał (ang.) |
| Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules |
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc. |
prismmediawire.com |
2024-10-02 23:12:13 |
Czytaj oryginał (ang.) |
| Oncocyte Signs Leading Transplant Centers in US and Germany |
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both have entered into agreements with the Company to utilize GraftAssure™, the Company's research-use-only assay (“GraftAssure”) that can detect early evidence of graft organ damage in patients' blood. |
globenewswire.com |
2024-10-02 22:41:00 |
Czytaj oryginał (ang.) |
| Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules |
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories |
globenewswire.com |
2024-10-02 22:35:00 |
Czytaj oryginał (ang.) |
| Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study |
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp. |
prismmediawire.com |
2024-08-12 20:30:33 |
Czytaj oryginał (ang.) |